CN108686226B - 以碱基为载体的纳米药物输送体系 - Google Patents
以碱基为载体的纳米药物输送体系 Download PDFInfo
- Publication number
- CN108686226B CN108686226B CN201810717553.7A CN201810717553A CN108686226B CN 108686226 B CN108686226 B CN 108686226B CN 201810717553 A CN201810717553 A CN 201810717553A CN 108686226 B CN108686226 B CN 108686226B
- Authority
- CN
- China
- Prior art keywords
- drug
- nano
- carrier
- mixed solution
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810717553.7A CN108686226B (zh) | 2018-07-03 | 2018-07-03 | 以碱基为载体的纳米药物输送体系 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810717553.7A CN108686226B (zh) | 2018-07-03 | 2018-07-03 | 以碱基为载体的纳米药物输送体系 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108686226A CN108686226A (zh) | 2018-10-23 |
CN108686226B true CN108686226B (zh) | 2020-05-22 |
Family
ID=63851295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810717553.7A Active CN108686226B (zh) | 2018-07-03 | 2018-07-03 | 以碱基为载体的纳米药物输送体系 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108686226B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110063962A (zh) * | 2019-04-24 | 2019-07-30 | 厦门大学 | 一种氯法拉滨甲氨蝶呤双药制剂及其制备方法 |
CN110934875A (zh) * | 2019-12-20 | 2020-03-31 | 厦门大学 | 一种5-氟尿嘧啶甲氨蝶呤双药制剂及其制备方法 |
CN114591386B (zh) * | 2022-05-10 | 2022-09-09 | 深圳厚存纳米药业有限公司 | 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1861049A (zh) * | 2006-03-17 | 2006-11-15 | 山东蓝金生物工程有限公司 | 一种含吉西他滨的抗癌药物缓释注射剂 |
CN103044437B (zh) * | 2012-12-21 | 2015-08-26 | 上海交通大学 | 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用 |
AR095962A1 (es) * | 2013-04-01 | 2015-11-25 | Moreinx Ab | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos |
CN103435671B (zh) * | 2013-08-12 | 2016-06-01 | 上海交通大学 | 基于核酸碱基的超分子磷脂及其制备方法、脂质体 |
CN105131066B (zh) * | 2015-07-31 | 2018-08-03 | 四川大学 | 一种嘧啶衍生物及其制备方法与用途 |
CN105535991B (zh) * | 2016-01-11 | 2018-08-31 | 上海交通大学 | 用于治疗肿瘤的两亲性碱基缀合物纳米颗粒及其制备方法 |
-
2018
- 2018-07-03 CN CN201810717553.7A patent/CN108686226B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108686226A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shi et al. | pH-Sensitive nanoscale materials as robust drug delivery systems for cancer therapy | |
CN108686226B (zh) | 以碱基为载体的纳米药物输送体系 | |
Fan et al. | Development of calixarene-based drug nanocarriers | |
Wang et al. | Supramolecularly engineered phospholipids constructed by nucleobase molecular recognition: upgraded generation of phospholipids for drug delivery | |
Zheng et al. | Lipid-polymer nanoparticles for folate-receptor targeting delivery of doxorubicin | |
US20220175953A1 (en) | Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery | |
ES2951598T3 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos | |
Han et al. | Redox-sensitive micelles for targeted intracellular delivery and combination chemotherapy of paclitaxel and all-trans-retinoid acid | |
CN106267149A (zh) | 一种ros响应的脑卒中智能药物载体及其制备方法 | |
CN110101685B (zh) | 一种仿生纳米药物、其制备方法及应用 | |
CN111956801A (zh) | 光控释放co和阿霉素的纳米药物系统及其制备和应用 | |
US20210346290A1 (en) | POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDa | |
CN102973512B (zh) | 负载阿霉素并具有叶酸受体靶向功能的白蛋白纳米粒子制剂及其制备方法 | |
CN101708335A (zh) | pH敏感树枝状聚合物药物载体 | |
Chen et al. | Dual-pH sensitive charge-reversal drug delivery system for highly precise and penetrative chemotherapy | |
CN108542893B (zh) | 一种具有优良血液稳定性能的纳米颗粒及其制备方法 | |
CN108186571B (zh) | 可逆交联不对称囊泡在制备治疗急性白血病药物中的应用 | |
CN103301073B (zh) | 一种甲氨喋呤靶向纳米粒缓释制剂及其制备方法 | |
CN111135314A (zh) | 一种用于胃癌早期诊断和治疗的纳米复合物及其制备方法 | |
CA3008095C (en) | A pharmaceutical composition comprising apatite-based matrix and surface modifying agent | |
Baviskar et al. | Development and evaluation of N-acetyl glucosamine-decorated vitamin-E-based micelles incorporating resveratrol for cancer therapy | |
CN110498877B (zh) | 聚(2-羧基丙烯酸)及其制备方法和应用 | |
CN103919738B (zh) | 一种甲氨喋呤前药及其胶束制剂和制备方法 | |
WO2018151258A1 (ja) | 薬物送達用担体及び薬物送達システム | |
Lobenberg | Smart materials: applications of nanotechnology in drug delivery and drug targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201124 Address after: Room 105G, 199 GuoShoujing Road, Pudong New Area, Shanghai, 200120 Patentee after: Shanghai Jiaotong University Intellectual Property Management Co.,Ltd. Address before: 200240 Dongchuan Road, Shanghai, No. 800, No. Patentee before: SHANGHAI JIAO TONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211117 Address after: 200240 No. 800, Dongchuan Road, Shanghai, Minhang District Patentee after: SHANGHAI JIAO TONG University Address before: Room 105G, 199 GuoShoujing Road, Pudong New Area, Shanghai, 200120 Patentee before: Shanghai Jiaotong University Intellectual Property Management Co.,Ltd. |
|
TR01 | Transfer of patent right |